At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
- Oxford Clinical Trials Research Unit which integrates the following trials groups:
- Centre for Statistics in Medicine
- Critical Care, Trauma and Rehabilitation Trials Group
- Gastroenterology Trials Group
- Oncology Clinical Trials Office (all phases)
- Respiratory Trials Unit
- Surgical Intervention Trials Unit (SITU)
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Group
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
18 May 2021
Researchers running the University of Oxford-led Com-COV study – launched earlier this year to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine – report preliminary data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules.
7 May 2021
First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.
28 April 2021
A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.